Celldex therapeutics, inc. (CLDX)
Income statement / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13Dec'12Sep'12Jun'12Mar'12Dec'11Sep'11Jun'11Mar'11Sep'10Jun'10
REVENUES:
Total Revenues

4,876

3,573

4,452

4,847

6,895

9,538

11,228

14,211

15,277

12,743

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Product Development and Licensing Agreements

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1,939

1,823

1,553

1,442

1,372

1,279

1,145

838

562

318

165

160

160

148

141

146

148

160

131

110

1,436

2,795

0

0

0

Contracts and Grants

-

-

-

-

-

-

-

-

-

-

-

-

-

-

4,763

3,685

4,744

4,038

3,795

3,963

2,511

2,748

2,167

2,290

1,948

1,617

1,092

231

277

281

234

0

0

-

0

-

-

-

-

Product Royalties

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

2,334

5,886

8,892

10,765

10,775

9,581

8,893

8,961

9,119

7,798

7,032

0

0

0

Total Revenues

-

-

-

-

-

-

-

-

-

-

-

-

-

-

6,702

5,508

6,297

5,480

5,167

5,242

3,656

3,586

2,729

2,608

2,113

4,111

7,138

9,271

11,183

11,202

9,989

9,239

9,182

9,265

9,239

9,827

0

0

0

OPERATING EXPENSES:
Research and Development

43,216

42,672

43,541

44,358

55,725

66,449

78,705

88,702

92,253

96,171

97,266

100,360

101,072

102,726

102,067

101,714

102,493

100,171

103,297

104,826

102,436

104,381

95,159

89,391

80,381

67,401

63,343

54,695

50,719

47,398

43,475

40,300

36,355

32,439

29,831

28,493

0

0

0

Royalty

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

2,334

5,886

8,892

10,765

10,775

9,581

8,893

8,961

9,119

7,979

7,393

0

0

0

Gain on Sale of Assets

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

General and Administrative

14,196

15,426

16,540

16,859

18,572

19,269

20,830

22,454

23,367

25,003

31,041

32,645

33,901

35,979

35,124

36,661

37,055

33,837

29,009

25,526

22,129

20,622

19,051

17,625

16,249

14,805

12,772

12,029

10,837

10,016

9,715

9,153

9,174

9,193

9,270

9,588

0

0

0

Goodwill Impairment

-

-

-

-

-

90,976

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Intangible Asset Impairment

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Intangible Asset Impairment

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other Asset Impairment

-

1,800

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Gain on Fair Value Remeasurement of Contingent Consideration

2,579

1,294

3,265

8,086

14,502

29,621

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Gain on Fair Value Remeasurement of Contingent Consideration

-

-

-

-

-

-

-

-

-

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Amortization of Acquired Intangible Assets

-

-

0

0

-

224

448

672

896

896

908

938

968

997

1,013

1,013

1,013

1,013

1,013

1,013

1,013

1,013

1,013

1,013

1,013

1,013

1,015

1,015

1,052

1,090

1,127

1,529

1,721

1,913

2,105

2,107

0

0

0

Total Operating Expenses

54,833

58,604

58,616

54,931

61,595

165,974

181,068

208,248

221,369

134,270

142,015

138,343

139,341

139,702

138,204

139,388

140,561

135,021

133,319

131,365

125,578

126,016

115,223

108,029

97,643

85,553

83,016

76,631

73,373

69,279

63,898

59,875

56,211

52,664

49,135

47,531

0

0

0

Operating Loss

-49,957

-55,031

-54,164

-50,084

-54,700

-156,436

-169,840

-194,037

-206,092

-121,527

-130,854

-128,886

-132,324

-132,916

-131,502

-133,880

-134,264

-129,541

-128,152

-126,123

-121,922

-122,430

-112,494

-105,421

-95,530

-81,442

-75,878

-67,360

-62,190

-58,077

-53,909

-50,636

-47,029

-43,399

-39,896

-37,704

0

0

0

Investment and Other Income, Net

3,693

4,153

4,331

4,421

4,409

4,487

4,370

4,247

4,143

4,214

4,157

4,154

4,206

4,386

2,595

2,591

2,568

2,344

1,818

3,687

3,571

4,350

4,258

2,140

2,026

819

776

739

704

530

0

0

0

-

-

-

-

-

-

Investment and Other Income, Net

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

0

Interest Expense

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

927

1,193

1,561

1,453

1,576

1,664

1,721

1,744

1,796

1,689

1,585

0

0

0

Net Loss Before Income Tax Benefit

-

-

-49,833

-45,663

-

-151,949

-165,470

-189,790

-201,949

-117,313

-123,988

0

0

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Income Tax Benefit

-

-

-

-

-

-765

-5,965

0

0

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net Loss

-46,264

-50,878

-49,833

-45,663

-50,291

-151,184

-145,623

-164,743

-176,902

-93,031

-121,497

-124,732

-128,118

-128,530

-128,907

-131,289

-131,696

-127,197

-126,334

-122,436

-118,351

-118,080

-108,321

-103,379

-94,121

-81,550

-76,295

-68,182

-62,939

-59,123

-55,048

-51,793

-48,256

-44,799

-41,154

0

0

0

-

Net Loss

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Basic and Diluted Net Loss Per Common Share

-0.73

-0.52

-0.75

-0.84

-1.40

0.46

-0.66

-1.67

-12.61

-10.15

-0.20

-0.23

-0.28

-18.03

-0.29

-0.32

-0.35

-0.33

-0.32

-0.33

-0.33

-0.36

-0.31

-0.32

-0.33

-0.26

-0.29

-0.24

-0.23

-0.27

-0.25

-0.23

-0.27

-0.28

-0.27

-0.27

-0.31

-0.28

-0.30

Shares Used in Calculating Basic and Diluted Net Loss per Share

17,406

16,497

15,282

13,952

12,297

11,657

10,912

9,829

9,370

-343,210

129,640

125,202

122,648

-271,102

100,672

98,817

98,689

98,717

98,568

98,482

92,437

89,561

89,404

89,361

89,270

83,167

81,015

80,899

74,027

62,507

59,467

58,733

50,145

-

44,136

37,463

-

-

-

COMPREHENSIVE LOSS:
Shares Used in Calculating Basic Net Loss per Share (Note 3) (in shares)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

32,047

31,922

31,815

Shares Used in Calculating Diluted Net Loss per Share (Note 3) (in shares)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

32,047

31,922

31,815

Net Loss

-46,264

-50,878

-49,833

-45,663

-50,291

-151,184

-145,623

-164,743

-176,902

-93,031

-121,497

-124,732

-128,118

-128,530

-128,907

-131,289

-131,696

-127,197

-126,334

-122,436

-118,351

-118,080

-108,321

-103,379

-94,121

-81,550

-76,295

-68,182

-62,939

-59,123

-55,048

-51,793

-48,256

-44,799

-41,154

0

0

0

-

Other Comprehensive Income (Loss):
Foreign Currency Translation Adjustments

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

15

14

11

9

-5

-4

-1

0

-3

-3

-2

-2

2

1

-3

-3

-9

0

0

0

-

-

Unrealized Gain on Marketable Securities

-5

36

53

48

43

19

-6

13

-3

23

-22

-146

-125

234

50

287

71

-298

-78

-323

-63

-73

-58

201

-19

-74

-86

-172

-71

91

120

-49

5

-90

0

0

0

-

-

Comprehensive Loss

-46,269

-50,842

-49,780

-45,615

-50,248

-151,165

-145,629

-164,730

-176,905

-93,008

-121,519

-124,878

-128,243

-128,296

-128,857

-131,002

-131,625

-127,480

-126,398

-122,748

-118,405

-118,158

-108,383

-103,179

-94,140

-81,627

-76,384

-68,356

-63,012

-59,030

-54,927

-51,845

-48,254

-44,898

0

0

0

-

-

Product Development and Licensing Agreements
Total Revenues

2,630

473

930

1,006

2,478

3,341

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Contracts and Grants
Total Revenues

2,246

3,100

3,522

3,841

4,417

6,197

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-